Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma

Franco Di Filippo, F. Cavaliere, M. Anzà, R. Garinei, C. Botti, P. Perri, P. Di Angelo, V. Patrizi, S. Di Filippo, P. Visca

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Liposome-containing doxorubicin has been employed in the treatment of advanced soft tissue limb sarcoma during hyperthermic perfusion. A phase I-II study was carried out starting with a standard dose of 10 mg//L of limb volume, the dosage was escalated with 2 mg for each triplet of patients. The maximum tolerable (MTD) dose was established as the amount able to cause a grade IV limb reaction at least in two out of three patients, the temperature level remained unchanged (41.5°C). The grade of limb reaction ranged between I-II (mild edema and erythema). Only in two patients treated with 18 mg/L of limb volume was a grade IV limb reaction observed, therefore MTD at a temperature of 41.5°C is 16 mg. A good tumor response was observed in 29% of the patients, partial response in 71%. The tumor shrinkage after perfusion permitted conservative surgery in 91% of the cases.

Original languageEnglish
Pages (from-to)66-69
Number of pages4
JournalJournal of Chemotherapy
Volume16
Issue numberSUPPL. 5
Publication statusPublished - Nov 2004

Fingerprint

Sarcoma
Extremities
Therapeutics
Perfusion
Temperature
Erythema
Liposomes
Doxorubicin
liposomal doxorubicin
Edema
Neoplasms

Keywords

  • Doxorubicin
  • Liposomal doxorubicin
  • Soft tissue limb sarcoma
  • TNFα

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Microbiology (medical)

Cite this

Di Filippo, F., Cavaliere, F., Anzà, M., Garinei, R., Botti, C., Perri, P., ... Visca, P. (2004). Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma. Journal of Chemotherapy, 16(SUPPL. 5), 66-69.

Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma. / Di Filippo, Franco; Cavaliere, F.; Anzà, M.; Garinei, R.; Botti, C.; Perri, P.; Di Angelo, P.; Patrizi, V.; Di Filippo, S.; Visca, P.

In: Journal of Chemotherapy, Vol. 16, No. SUPPL. 5, 11.2004, p. 66-69.

Research output: Contribution to journalArticle

Di Filippo, F, Cavaliere, F, Anzà, M, Garinei, R, Botti, C, Perri, P, Di Angelo, P, Patrizi, V, Di Filippo, S & Visca, P 2004, 'Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma', Journal of Chemotherapy, vol. 16, no. SUPPL. 5, pp. 66-69.
Di Filippo F, Cavaliere F, Anzà M, Garinei R, Botti C, Perri P et al. Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma. Journal of Chemotherapy. 2004 Nov;16(SUPPL. 5):66-69.
Di Filippo, Franco ; Cavaliere, F. ; Anzà, M. ; Garinei, R. ; Botti, C. ; Perri, P. ; Di Angelo, P. ; Patrizi, V. ; Di Filippo, S. ; Visca, P. / Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma. In: Journal of Chemotherapy. 2004 ; Vol. 16, No. SUPPL. 5. pp. 66-69.
@article{f910f4a7a2bc434db6c5c1251ccc0fe1,
title = "Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma",
abstract = "Liposome-containing doxorubicin has been employed in the treatment of advanced soft tissue limb sarcoma during hyperthermic perfusion. A phase I-II study was carried out starting with a standard dose of 10 mg//L of limb volume, the dosage was escalated with 2 mg for each triplet of patients. The maximum tolerable (MTD) dose was established as the amount able to cause a grade IV limb reaction at least in two out of three patients, the temperature level remained unchanged (41.5°C). The grade of limb reaction ranged between I-II (mild edema and erythema). Only in two patients treated with 18 mg/L of limb volume was a grade IV limb reaction observed, therefore MTD at a temperature of 41.5°C is 16 mg. A good tumor response was observed in 29{\%} of the patients, partial response in 71{\%}. The tumor shrinkage after perfusion permitted conservative surgery in 91{\%} of the cases.",
keywords = "Doxorubicin, Liposomal doxorubicin, Soft tissue limb sarcoma, TNFα",
author = "{Di Filippo}, Franco and F. Cavaliere and M. Anz{\`a} and R. Garinei and C. Botti and P. Perri and {Di Angelo}, P. and V. Patrizi and {Di Filippo}, S. and P. Visca",
year = "2004",
month = "11",
language = "English",
volume = "16",
pages = "66--69",
journal = "Journal of Chemotherapy",
issn = "1120-009X",
publisher = "Maney Publishing",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Liposomal doxorubicin in the perfusional treatment of advanced soft tissue limb sarcoma

AU - Di Filippo, Franco

AU - Cavaliere, F.

AU - Anzà, M.

AU - Garinei, R.

AU - Botti, C.

AU - Perri, P.

AU - Di Angelo, P.

AU - Patrizi, V.

AU - Di Filippo, S.

AU - Visca, P.

PY - 2004/11

Y1 - 2004/11

N2 - Liposome-containing doxorubicin has been employed in the treatment of advanced soft tissue limb sarcoma during hyperthermic perfusion. A phase I-II study was carried out starting with a standard dose of 10 mg//L of limb volume, the dosage was escalated with 2 mg for each triplet of patients. The maximum tolerable (MTD) dose was established as the amount able to cause a grade IV limb reaction at least in two out of three patients, the temperature level remained unchanged (41.5°C). The grade of limb reaction ranged between I-II (mild edema and erythema). Only in two patients treated with 18 mg/L of limb volume was a grade IV limb reaction observed, therefore MTD at a temperature of 41.5°C is 16 mg. A good tumor response was observed in 29% of the patients, partial response in 71%. The tumor shrinkage after perfusion permitted conservative surgery in 91% of the cases.

AB - Liposome-containing doxorubicin has been employed in the treatment of advanced soft tissue limb sarcoma during hyperthermic perfusion. A phase I-II study was carried out starting with a standard dose of 10 mg//L of limb volume, the dosage was escalated with 2 mg for each triplet of patients. The maximum tolerable (MTD) dose was established as the amount able to cause a grade IV limb reaction at least in two out of three patients, the temperature level remained unchanged (41.5°C). The grade of limb reaction ranged between I-II (mild edema and erythema). Only in two patients treated with 18 mg/L of limb volume was a grade IV limb reaction observed, therefore MTD at a temperature of 41.5°C is 16 mg. A good tumor response was observed in 29% of the patients, partial response in 71%. The tumor shrinkage after perfusion permitted conservative surgery in 91% of the cases.

KW - Doxorubicin

KW - Liposomal doxorubicin

KW - Soft tissue limb sarcoma

KW - TNFα

UR - http://www.scopus.com/inward/record.url?scp=19944427489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944427489&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 66

EP - 69

JO - Journal of Chemotherapy

JF - Journal of Chemotherapy

SN - 1120-009X

IS - SUPPL. 5

ER -